Spectrum Pharmaceuticals, Inc., (Nasdaq: SPPI) announced results of a Phase 2b study of EOquin, in non-invasive bladder cancer and the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE